# A Study of CDX-0159 in Patients With Prurigo Nodularis

> **NCT04944862** · PHASE1 · COMPLETED · sponsor: **Celldex Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **BIOLOGICAL:** CDX-0159
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT04944862
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-08
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04944862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04944862, "A Study of CDX-0159 in Patients With Prurigo Nodularis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04944862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*